Toronto – February 24, 2023 – The Canadian Nuclear Isotope Council (CNIC) is pleased to announce its recent accomplishment in achieving Not-for-Profit status. In collaboration with the CNIC’s new Board of Directors, the CNIC has worked diligently over the last several months to take this important step as the voice of Canada’s isotope industry. Formed … Read more
Toronto – February 7, 2023 – ACIC Pharmaceutical Machinery, a Canadian company located in Brantford, ON, is the newest member of the Canadian Nuclear Isotope Council (CNIC). ACIC Machinery provides complete equipment and automation solutions needed to manufacture radiopharmaceuticals. Together, the CNIC and ACIC Machinery will work to encourage future partnerships by bringing industry-leading technology … Read more
Toronto – December 20, 2022 – The Canadian Nuclear Isotope Council (CNIC) is pleased to announce a partnership with ARC Clean Technology (ARC). As a member of the CNIC, ARC joins 76+ organizations and companies in Canada’s isotope community that work together to advance Canada’s role in the global supply chain for nuclear isotopes. ARC … Read more
Toronto – November 10, 2022 – There is mounting concern in Canada and around the world that a global medical isotope shortage of Molybdenum-99 (Mo-99) is impacting patients. As a result, doctors will have to start rescheduling patients in need of diagnostic procedure and prioritizing urgent scans. In the interim, hospitals may also have to … Read more
Toronto – November 2, 2022 – AtomVie Global Radiopharma Inc. (AtomVie), a manufacturer and supplier of multiple finished-dose therapeutic radiopharmaceutical products, is the newest member of the Canadian Nuclear Isotope Council (CNIC). AtomVie has developed over 7 years of experience in the GMP manufacturing and global distribution of radiopharmaceuticals as the former CMO business unit … Read more
Toronto, Ontario – October 25, 2022 – Yesterday, the international partnership between Bruce Power, Isogen (a Kinectrics and Framatome company), and ITM Isotope Technologies Munich (ITM), announced the start of commercial production of lutetium-177. Lutetium-177 is a medical isotope used for targeted cancer therapies. The properties of the isotope allow it to bond with a … Read more
Company Highlights Growing Nuclear Medicine Product Portfolio and Future Opportunities in Therapeutic Radioisotopes (OTTAWA, ON – September 13, 2022) – BWX Technologies, Inc. (NYSE: BWXT) announced today that subsidiary BWXT Medical Ltd. has submitted a new drug application to the U.S. Food and Drug Administration (FDA) to request approval of its technetium-99m (Tc-99m) generator for … Read more
Toronto – August 16, 2022 – The Canadian Nuclear Isotope Council (CNIC) is proud to participate in a joint Industry Statement to the Tenth Review Conference of the Parties to the Treaty on the Non-Proliferation of Nuclear Weapons (NPT) alongside international and national industry associations covering a wide variety of nuclear applications. The NPT importantly … Read more
(OTTAWA, ON – June 13, 2022) – BWX Technologies, Inc. (NYSE: BWXT) announced today that subsidiary BWXT Medical Ltd. and TRIUMF, Canada’s particle accelerator centre, have executed a licensing and services agreement that strengthens their existing partnership for the production of medical isotopes. This agreement will enable BWXT Medical to manufacture high purity Actinium-225 (Ac-225) … Read more
THIS POSITION IS NOW FILLED Job Overview Policy, Government and Stakeholder Relations Specialist at the CNIC is responsible for connecting federal, provincial, and municipal political leaders to the organization and the broader Canadian Isotope Ecosystem. Reporting to the Executive Director, this position is responsible for public outreach, engagement, and education efforts. The specialist will also … Read more